Elahere
AbbVie's Elahere Approved in Europe for FRα-Positive Ovarian Cancer
Elahere's companion diagnostic, Roche's Ventana FOLR1 (FOLR1-2.1) RxDx assay, also garnered CE marking.
Merck, Daiichi Sankyo Begin Phase II/III Trial of R-DXd in Advanced Ovarian Cancer
Although patients aren't required to express CDH6 to be eligible, the drugmakers will measure biomarker expression levels as one of the trial's endpoints.
ImmunoGen Achieves Full FDA Approval for Elahere in Folate Receptor Alpha-Positive Ovarian Cancer
The agency made the decision after reviewing results from the confirmatory Phase III MIRASOL clinical trial.
ImmunoGen to Share Data With Regulators Showing Elahere Benefit Across Ovarian Cancer Subgroups
Elahere benefited patients with FRα-positive ovarian cancer regardless of how many prior treatments they had received and if they had received a PARP inhibitor.